NCT06221813View on ClinicalTrials.gov

Study to Evaluate Safety and Immunogenicity of a Prime-Boost Regimen of rVSV-Nipah Virus Vaccine Candidate PHV02 in Healthy Adult Subjects

PHASE1CompletedINTERVENTIONAL

Enrollment

120

Participants

Timeline

Start Date

January 26, 2024

Primary Completion Date

September 30, 2024

Study Completion Date

October 2, 2024

Conditions

Nipah Virus Infection

Interventions

BIOLOGICAL

PHV02

Nipah virus vaccine

BIOLOGICAL

Lactated Ringer's

Placebo

Trial Locations (3)

33024

Cenexel RCA (Research Centers of America), Hollywood

84107

Cenexel JBR (JBR Clinical Research), Salt Lake City

92801

Cenexel ACT (Anaheim Clinical Trials), Anaheim

All Listed Sponsors

collaborator

Coalition for Epidemic Preparedness Innovations

OTHER

lead

Public Health Vaccines LLC

INDUSTRY

NCT06221813 - Study to Evaluate Safety and Immunogenicity of a Prime-Boost Regimen of rVSV-Nipah Virus Vaccine Candidate PHV02 in Healthy Adult Subjects | Biotech Hunter | Biotech Hunter